Paxman
Paxman AB develops and commercializes scalp cooling systems used to reduce chemotherapy-induced hair loss. The group is headquartered in Sweden and operates through subsidiaries in the UK, the US, Canada and other markets, serving hospitals and oncology clinics worldwide.
Fiscal year 2024 · change from previous year
Development 2021–2024
Business
Share of revenueMedical devices used during chemotherapy to reduce hair loss.
Caps, connectors and related items used with installed systems.
Installed-base revenue from rental and placement agreements.
Customer support, onboarding and clinical training for users.
Development of next-generation cooling and neuropathy devices.
Customers
Paxman sells primarily to hospitals, oncology centers and community cancer clinics that administer chemotherapy and need a scalp cooling solution for patients. In some markets, systems are placed through rental or signed delivery agreements, while in others they are sold outright to the customer. The end user is the patient, but the purchasing decision is typically made by clinical, operational and reimbursement stakeholders within the treatment center.
Buy installed scalp cooling systems to offer supportive care during chemotherapy.
Adopt the system to improve patient experience and broaden service offerings.
Use signed delivery and rental agreements for installed systems and recurring use.
Purchase systems for sale or deployment in markets outside North America.
Influence adoption by creating demand for hair-loss mitigation during treatment.
Strategy
Paxman is building out a broader oncology side-effect management platform around its scalp cooling franchise. Its priorities include clinical evidence generation, reimbursement expansion in the US, and commercialization of next-generation products such as a neuropathy-prevention device and a new cooling cap. The company is also integrating acquired operations into a unified structure to support scale and cross-selling.
Coverage and payment drive utilization, adoption and recurring revenue in the largest market.
Trials and studies strengthen physician confidence and payer support for broader use.
New devices reduce dependence on a single product category and widen the addressable market.
A unified structure can improve execution, customer service and scalability.
Geography
Paxman is based in Sweden, with production and sales carried out through its UK subsidiary and operating entities in the US and Canada. Reported installed systems span Europe, Asia, North America, the UK, South America and Oceania, showing a broad international footprint. North America is especially important because the company uses rental and delivery agreements there, while other regions are more often served through direct sales.
Risks
Paxman depends on adoption by healthcare providers and on reimbursement decisions, especially in the US where payment coverage can materially affect utilization. The business also faces execution risk from integrating acquired operations, scaling manufacturing and bringing new products through clinical and regulatory pathways. As a medical device company, it is exposed to clinical evidence risk, regulatory approval risk and competition from alternative supportive-care solutions.
- Reimbursement dependence in the USImpact: HighLikelihood: Low
Coverage and payment determine whether clinics can justify adoption and patients can access treatment.
Exposure: US oncology clinics and community cancer centers
- Integration risk after acquisitionImpact: High
Combining systems, teams and processes can create temporary disruption and execution complexity.
Exposure: Global operations and customer support
- Clinical and regulatory riskImpact: MediumLikelihood: Low
New products need supportive data and approvals before broad commercialization.
Exposure: Neuropathy-prevention device and next-generation cap
- Competitive pressureImpact: Medium
Alternative scalp cooling providers and other supportive-care options can limit pricing and share gains.
Exposure: International scalp cooling markets
Accounting
Judgemental itemsRental, delivery and sale arrangements can shift when revenue is recognized.
Impact: Affects quarterly comparability and installed-base revenue timing
The Dignitana acquisition requires valuation of acquired assets and liabilities.
Impact: Can materially affect amortization and reported earnings
Acquired technology and development assets may be amortized or impaired over time.
Impact: Influences operating profit and balance sheet carrying values
New product programs may involve judgment on capitalization versus expense.
Impact: Affects EBITDA, profit and asset base
Similar listed companies
Publicly listed companies with a comparable business focus.
Active Biotech
ACTI · Health Care
Active Biotech AB is a biotechnology company focused on developing first-in-class immunomodulatory treatments for oncology and immunology indications.
Oncopeptides
ONCO · Health Care
Oncopeptides is a Swedish biopharmaceutical company focused on developing and commercializing therapies for difficult-to-treat hematological diseases.
Isofol Medical
ISOFOL · Health Care
Isofol Medical AB is a Swedish biotechnology company focused on the development of arfolitixorin, a drug candidate aimed at improving treatment outcomes for metastatic colorectal cancer.
ALX Oncology Holdings Inc
ALXO · Pharmaceutical Preparations
ALX Oncology Holdings Inc is a clinical-stage biotechnology company developing immuno-oncology therapies for cancer, headquartered in South San Francisco, California.
Ascelia Pharma
ACE · Health Care
Ascelia Pharma is a Swedish pharmaceutical company headquartered in Malmö, with a US base in New Jersey.
Railcare Group
RAIL · Industrials
Railcare Group AB is a railway specialist company based in Skellefteå, Sweden, focusing on providing innovative products and services for railway maintenance and operations.
Last updated: 24/09/2026